Abstract
Combinations of the human immunodeficiency virus (HIV) Tat protein antagonist Ro 24-7429 with either the HIV protease inhibitor Ro 31-8959 or the HIV reverse transcriptase inhibitors AZT (3'-azido-3'-deoxythymidine), ddC (2',3'-dideoxycytidine), ddI (2',3'-dideoxyinosine), and nevirapine were synergistic or additive in reducing HIV type 1 p24 antigen production in CEM cells or inhibiting HIV type 1-induced syncytium formation in HT4-6C cells.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Antiviral Agents / pharmacology*
-
Benzodiazepines / pharmacology*
-
Didanosine / pharmacology
-
Drug Synergism
-
Gene Products, tat / antagonists & inhibitors*
-
HIV / drug effects
-
HIV / enzymology
-
HIV Protease Inhibitors / pharmacology*
-
HeLa Cells
-
Humans
-
Isoquinolines / pharmacology*
-
Nevirapine
-
Pyridines / pharmacology
-
Pyrroles*
-
Quinolines / pharmacology*
-
Reverse Transcriptase Inhibitors*
-
Saquinavir
-
Zalcitabine / pharmacology
-
Zidovudine / pharmacology
-
tat Gene Products, Human Immunodeficiency Virus
Substances
-
Antiviral Agents
-
Gene Products, tat
-
HIV Protease Inhibitors
-
Isoquinolines
-
Pyridines
-
Pyrroles
-
Quinolines
-
Reverse Transcriptase Inhibitors
-
tat Gene Products, Human Immunodeficiency Virus
-
Benzodiazepines
-
Ro 24-7429
-
Zidovudine
-
Zalcitabine
-
Nevirapine
-
Didanosine
-
Saquinavir